Efficacy and Safety of Jueyin Granules for Patients with Mild-to-Moderate Psoriasis Vulgaris: Protocol for a Multicenter Randomized Placebo-Controlled Trial

Su Li, Cang Zhang, Hong-Ya Zhang, Meng Zhou, Si-Nong Wang, Rong Xu, Dong-Mei Zhou, Yun-Run Ji, Jing-Jing Lv, Qing-Feng Yin, Rui-Ping Wang, Wei Li, Yan-Ping Liu, Jian-Feng Wang, Bin Li, Xin Li, Su Li, Cang Zhang, Hong-Ya Zhang, Meng Zhou, Si-Nong Wang, Rong Xu, Dong-Mei Zhou, Yun-Run Ji, Jing-Jing Lv, Qing-Feng Yin, Rui-Ping Wang, Wei Li, Yan-Ping Liu, Jian-Feng Wang, Bin Li, Xin Li

Abstract

Introduction. The etiology and pathogenesis of psoriasis are complex. Blood-heat syndrome is the core pathogenesis of psoriasis. Based on theories of Chinese medicine (CM), heat-clearing and blood-cooling (HCBC) are the primary treatment. Very few studies have investigated the pharmacological mechanism of the CM HCBC method for treating psoriasis. This multicenter randomized controlled trial will focus on treating psoriasis blood-heat syndrome with the HCBC method using Jueyin granules (JYKL). This will be an objective and standardized evaluation of the efficacy, safety, and reproducibility of the HCBC method to obtain objective evidence meeting international standards that aim to establish a clinical standard suitable for the popular application of CM for treating psoriasis. Methods and Analysis. A five-center randomized double-blind placebo-controlled clinical design will be used in this study. At least 196 participants will be randomly assigned to receive either JYKL or placebo treatment approximately 30 minutes after meals in the morning and evening (one sachet per time, twice daily for 8 consecutive weeks). The study duration will be 17 weeks, including 1 week of screening, 8 weeks of intervention, and 8 weeks of follow-up. The patients will be evaluated every 2 weeks, and the measures will be compared with baseline values. The primary outcome measure will be the psoriasis lesion area severity index. We will also observe the recurrence rate, body surface area, physician global assessment, dermatology life quality index, quality of life index, visual analogue scale score, CM symptom score, combined drug use, and adverse events. This trial is registered with NCT03961230.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Copyright © 2020 Su Li et al.

Figures

Figure 1
Figure 1
Flow diagram of the study process.

References

    1. Li X., Miao X., Wang H., et al. Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis. Medicine. 2016;95(19):p. e3676. doi: 10.1097/md.0000000000003676.
    1. Xing M., Yan X., Yang S., et al. Effects of moving cupping therapy for plaque psoriasis: study protocol for a randomized multicenter clinical trial. Trials. 2020;26(1):p. 21. doi: 10.1186/s13063-020-4155-0.
    1. Li X., Kong L., Li F., et al. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PloS One. 2015;10(12) doi: 10.1371/journal.pone.0145221.e0145221
    1. Wagner E. F., Schonthaler H. B., Guinea-Viniegra J., Tschachler E. Psoriasis: what we have learned from mouse models. Nature Reviews Rheumatology. 2010;6(12):704–714. doi: 10.1038/nrrheum.2010.157.
    1. Boehncke W.-H., Schön M. P. Psoriasis. The Lancet. 2015;386(9997):983–994. doi: 10.1016/s0140-6736(14)61909-7.
    1. Lewis-Beck C., Freddie M., Abouzaid S., et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Preference and Adherence. 2013;7:199–205. doi: 10.2147/ppa.s39887.
    1. Lowes M. A., Suárez-Fariñas M., Krueger J. G. Immunology of psoriasis. Annual Review of Immunology. 2014;32(1):227–255. doi: 10.1146/annurev-immunol-032713-120225.
    1. Luo Y., Ru Y., Zhao H., et al. Establishment of mouse models of psoriasis with blood stasis syndrome complicated with glucose and lipid metabolism disorders. Evidence-Based Complementary and Alternative Medicine. 2019;2019:10. doi: 10.1155/2019/6419509.6419509
    1. Grozdev I., Kast D., Cao L., et al. Physical and mental impact of psoriasis severity as measured by the compact short form-12 health survey (SF-12) quality of life tool. Journal of Investigative Dermatology. 2012;132(4):1111–1116. doi: 10.1038/jid.2011.427.
    1. Fan B., Li X., Ze K., et al. Expression of T-helper 17 cells and signal transducers in patients with psoriasis vulgaris of blood-heat syndrome and blood-stasis syndrome. Chinese Journal of Integrative Medicine. 2015;21(1):10–16. doi: 10.1007/s11655-014-1769-7.
    1. Cao X., Xu R., Li F., et al. TCM treatment of psoriasis. Medicine Reviews. 2015;21(1):117–118.
    1. Luo Y., Ru Y., Sun X., et al. Characteristics of psoriasis vulgaris in China: a prospective cohort study protocol. Annals of Translational Medicine. 2019;7(22):694. doi: 10.21037/atm.2019.10.46.
    1. Wang G., Liu Y. Traditional Chinese medicine is effective and safe in the treatment of psoriasis. International Journal of Dermatology. 2004;43(7):p. 552. doi: 10.1111/j.1365-4632.2004.02181.x.
    1. Li X., Xiao Q. Q., Li F. L., et al. Immune signatures in patients with psoriasis vulgaris of blood-heat syndrome: a systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine. 2016;2016:11. doi: 10.1155/2016/9503652.9503652
    1. Ru Y., Yan X.-N., Yang S.-Q., et al. Oral Taodan granules for mild-to-moderate psoriasis vulgaris: protocol for a randomized, double-blind, multicenter clinical trial. Annals of Translational Medicine. 2019;7(18):p. 488. doi: 10.21037/atm.2019.09.05.
    1. Chen Y., Guo D. J., Deng H., et al. Acute and chronic toxicity of a polyherbal preparation-Jueyin granules. BMC Complementary and Alternative Medicine. 2018;18(1):p. 148. doi: 10.1186/s12906-018-2211-z.
    1. Ma T., Jiang W.-c., Li X., et al. Effects of Chinese formula Jueyin granules on psoriasis in an animal model. Evidence-Based Complementary and Alternative Medicine. 2014;2014(3):1–8. doi: 10.1155/2014/512562.
    1. Huang X., Lv B., Zhang S., et al. Effects of radix curcumae-derived diterpenoid C onHelicobacter pylori-induced inflammation and nuclear factor kappa B signal pathways. World Journal of Gastroenterology. 2013;19(31):p. 5085. doi: 10.3748/wjg.v19.i31.5085.
    1. Jiang L., Lu Y., Jin J., et al. N-butanol extract from folium isatidis inhibits lipopolysaccharide-induced inflammatory cytokine production in macrophages and protects mice against lipopolysaccharide-induced endotoxic shock. Drug Design, Development and Therapy. 2015;2015(9):5601–5609. doi: 10.2147/DDDT.S89924.
    1. Kao S.-T., Liu C.-J., Yeh C.-C. Protective and immunomodulatory effect of Flos Lonicerae japonicae by augmenting IL-10 expression in a murine model of acute lung inflammation. Journal of Ethnopharmacology. 2015;168:108–115. doi: 10.1016/j.jep.2015.03.012.
    1. Jiang M., Han Y. Q., Zhou M. G., et al. The screening research of anti-inflammatory bioactive markers from different flowering phases of Flos Lonicerae Japonicae. PLoS One. 2014;9(5) doi: 10.1371/journal.pone.0096214.e96214
    1. Zhu H., Liang Q. H., Xiong X. G., et al. Anti-inflammatory effects of the bioactive compound Ferulic acid contained in Oldenlandia diffusa on collageninduced arthritis in rats. Evidence-Based Complementary and Alternative Medicine. 2014;2014(12):10. doi: 10.1155/2014/573801.573801
    1. Chen Z. C., Wu S. Y. S., Su W. Y., et al. Anti-inflammatory and burn injury wound healing properties of the shell of Haliotis diversicolor. BMC Complementary and Alternative Medicine. 2016;16(1):p. 487. doi: 10.1186/s12906-016-1473-6.
    1. Jingjing L. ü, Wang Y., Zhao W., et al. Effects of catalpol, L-shikonin and paeonol extracted from radix rehmanniae, radix arnebiae and cortex moutan on KGF-induced HaCaT cell proliferation. National Medical Journal of China. 2014;94(16):1265–1269.
    1. Corson T. W., Crews C. M. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 2007;130(5):769–774. doi: 10.1016/j.cell.2007.08.021.
    1. Dermatology Branch of Chinese Society of traditional Chinese Medicine. Psoriasis vulgaris (psoriasis vulgaris) evidence-based clinical practice guide of traditional Chinese medicine (2013 edition) Journal of Traditional Chinese Medicine. 2014;55(1):p. 7682.
    1. Iversen L., Lange M. M., Bissonette R., et al. Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. Journal of the European Academy of Dermatology and Venereology. 2017;31(7):1188–1195. doi: 10.1111/jdv.14250.
    1. Duffin K. C., Papp K. A., Bagel J., Levi E, Chen R, Gottlieb A. B. Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2. Journal of Drugs in Dermatology. 2017;16(16):147–153.
    1. Thaçi D., Kimball A., Foley P., et al. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. Journal of the European Academy of Dermatology and Venereology. 2017;31(3):498–506. doi: 10.1111/jdv.13918.
    1. Yao D. Construction of Psoriasis Vulgaris Main Symptom Scale and Study on Clinical Minimum Important Difference of DLQI scale. Guangzhou, China: Guangzhou University of TCM; 2015.
    1. Langley R. G. B. Psoriasis: epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases. 2005;64(2):ii18–ii23. doi: 10.1136/ard.2004.033217.
    1. Shah Y. M., Didarally Khodabocus K., Kadam Y. R., et al. Impact of psoriasis on the quality of life. National Journal of Community Medicine. 2015;6(4):469–473.
    1. Stenberg B., Bergbrant I. M., Stenberg B., Svensson Å. Patients’ visual analogue scale: a useful method for assessing psoriasis severity. Acta Dermato Venereologica. 2012;92(4):p. 347. doi: 10.2340/00015555-1237.
    1. Li F. l., Li B., Xu R., et al. Qinzhu Liangxue Decoction in treatment of blood-heat type psoriasis vulgaris: a randomized controlled trial. Journal of Chinese Integrative Medicine. 2008;6(6):586–590. doi: 10.3736/jcim20080608.
    1. Chen X., Hong S., Sun X., et al. Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trials. Nutrition Reviews. 2020;2020 doi: 10.1093/nutrit/nuz098.
    1. Zhang Z., Zhang B., Yan Y., et al. Observation on the therapeutic effect of traditional Chinese medicine PSORI-CM01 granule combined with hot spring and coal tar in the treatment of psoriasis vulgaris. Guangdong Med. 2018;11:1734–1717.
    1. Zheng Q., Jiang W., Sun X., et al. Total glucosides of paeony for the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2019;62:p. 152940.
    1. WHO. 2016 Global Report on Psoriasis. Geneva, Switzerland: WHO; 2016. .
    1. Wong Y., Nakamizo S., Tan K. J., Kabashima K. An update on the role of adipose tissues in psoriasis. Frontiers in Immunology. 2019;10:p. 1507. doi: 10.3389/fimmu.2019.01507.
    1. Yeung H., Takeshita J., Mehta N. N., et al. Psoriasis severity and the prevalence of major medical comorbidity. JAMA Dermatology. 2013;149(10):p. 1173. doi: 10.1001/jamadermatol.2013.5015.
    1. Liu J., Yanyan F., Pu X. Epidemiology of psoriasis and metabolic syndrome. Journal of Practice Dermatology. 2014;7(6):4444–4446.
    1. Zheng Q., Sun X. Y., Miao X., et al. Association between physical activity and risk of prevalent psoriasis: a MOOSE-compliant meta-analysis. Medicine. 2018;97(27) doi: 10.1097/md.0000000000011394.e11394
    1. O’Leary C. J., Creamer D., Higgins E., Weinman J. Perceived stress, stress attributions and psychological distress in psoriasis. Journal of Psychosomatic Research. 2004;57(5):465–471. doi: 10.1016/j.jpsychores.2004.03.012.
    1. Fordham B., Griffiths C. E. M., Bundy C. A pilot study examining mindfulness-based cognitive therapy in psoriasis. Psychology, Health & Medicine. 2015;20(1):121–127. doi: 10.1080/13548506.2014.902483.
    1. Pal H. C., Chamcheu J. C., Adhami V. M., et al. Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse model by inducing epidermal differentiation and inhibiting inflammation. British Journal of Dermatology. 2014;172(2):354–364. doi: 10.1111/bjd.13513.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner